GPAM and hepatocellular carcinoma: Furthermore, in hepatocellular carcinoma, BMAL1 was shown to transcriptionally inhibit glycerol-3-phosphate acyltransferase mitochondrial (GPAM) expression in an Enhancer of zeste homolog 2 (EZH2)-dependent manner, suppressing tumor cell growth by interfering with glycolipid metabolic processes [19].